One Health News

 
Search News:
 
Found 954 Matching Results. View archived News Here.

One Health Lecture - April 11, 2018-- The Oncopig Cancer Model (OCM):A PLatform for Transitional, Translational and Transformative Advances in Cancer Research - Monday, March 19, 2018

 

One Health Lecture

The Oncopig Cancer Model (OCM): A Platform for Transitional, Translational and Transformative Advances in Cancer Research

SEE: https://vetmed.iastate.edu/research-grad-studies/centers-institutes-and-initiatives/one-health/one-health-lecture-oncopig-cancer-model-ocm

 Wednesday, April 11
5:30 pm
College of Veterinary Medicine
Room 2226 Vet Med
Recorded link pending
Livestream link  https://echo360.org/section/948100ee-fe9d-494e-a91a-19fd0aa56673/public

Presented by Dr. Lawrence B. Schook,

Lawrence B. Schook, PhD, Edward William and Jane Marr Gutsgell Professor of Animal Sciences and Radiology, previously served as the Vice President for Research at the University of Illinois, overseeing the technology commercialization and economic development activities across the University’s three campuses (Urbana-Champaign, Chicago, Springfield). Previously, he served as founding Director, UIUC Division of Biomedical Sciences and the founding Woese Institute for Genomic Biology (IGB) Theme Leader for Regenerative Biology and Tissue Engineering. Dr. Schook is a recognized international scholar in comparative genomics and is known for leading the pig genome-sequencing project, which has provided researchers insights into human cancer and other chronic diseases. He is a noted entrepreneur who has launched three health startup companies. Schook is currently funded by the NIH and the DOD to develop the pig as a biomedical cancer model and has been the PI in extramural funding from the NIH, NSF and USDA. He has co-authored/edited nine books and over 250 publications, has trained 43 graduate students, mentored 35 undergraduate projects and 25 postgraduate scholars. He has appointments in bioengineering, nutritional sciences, veterinary pathobiology, pathology, surgery, the Institute for Genomic Biology and the Beckman Institute. He was a Fellow at the Academy for Entrepreneurial Leadership and the National Center for Supercomputer Applications. Dr. Schook is a founding director of UI LABS, a Chicago-based research and commercialization collaborative that spun out of the University. A Fellow of the American Association for the Advancement of Science, he currently serves on the Board of Trustees for Albion College, and the boards of the National Academy of Sciences Institute for Laboratory Animal Science Council, Translational Research and Innovative Oncology, Inc., Onclavus, Inc., and the Illinois Technology Association Internet of Things Council. He previously served on the Board of Managers for the Fermi and Argonne National Laboratories, and Illinois Governor Quinn’s Innovation Council. Dr. Schook obtained Postdoctoral Fellowships from the Institute of Clinical Immunology, University of Berne, Switzerland and University of Michigan School of Medicine, Ann Arbor; Ph.D. from the Wayne State School of Medicine, Detroit, Michigan; and B.A. from Albion College, Michigan.

The One Health Lecture Series was established in the College of Veterinary Medicine at Iowa State University in honor of Dr. Roger Mahr, DVM Class of 1971

Provided March 19, 2018 by:

Claire B. Andreasen DVM, PhD, Diplomate ACVP

Professor, Department of Veterinary Pathology

Director of One Health

College of Veterinary Medicine

Iowa State University

 

Dr. Andreasen is a longstanding One Health Supporter/Advocate http://www.onehealthinitiative.com/supporters.php.


TATFAR kicked off their 2018 Meeting in Atlanta - One Health Solutions - Tuesday, March 13, 2018

TATFAR kicked off their 2018 Meeting in Atlanta

Experts strengthened collaboration to improve antibiotic use in humans and animals, prevent infections and their spread, and strengthen the drug pipeline.
Canada · European Union · Norway · United States

 

2018 TATFAR meeting

TATFAR creates opportunities to address AMR with comprehensive, One Health solutions.

 

On March 7-8, a two-day Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) meeting was held in Atlanta. TATFAR members convened to strengthen collaboration against growing resistance to life-saving antimicrobial drugs. The meeting included government agency representatives from Canada, the European Union, Norway, and the United States, along with other leading experts on antimicrobial resistance (AMR).

The meeting covered topics including:

  • maximizing partner engagement to motivate action on AMR;
  • strategies to support local level action on AMR and government collaboration to implement National Action Plans;
  • improving antibiotic use in human medicine; and
  • current methodologies for measuring antimicrobial consumption of animals by species and the possibilities for alignment.

The second day opened with a plenary session devoted to strategies for improving the pipeline of new antimicrobial drugs, one of TATFAR’s three key areas. In the afternoon, attendees gathered for the breakout sessions to develop work plans for the second half of TATFAR’s current implementation period.

TATFAR was created in 2009 to address the urgent threat of AMR. Collaboration across government agencies enhances synergy and communication, leading to strengthened domestic and global efforts. These relationships gained through TATFAR will continue beyond the meeting, allowing technical experts to support global action and facilitate progress in addressing AMR.

Read two stories summarizing the meeting’s events—which included keynote speakers Xavier Prats-Monné, Director General for Health and Food Safety within the European Commission, and Anne Schuchat, Acting CDC Director—on the TATFAR website:

 


U.S. National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) Physician Director, Dr. Anthony S. Fauci Addresses One Health... - Friday, March 09, 2018

U.S. National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) Physician Director, Dr. Anthony S. Fauci Addresses One Health...

The One Health Initiative Autonomous pro bono Team has had many positive comments on our recent paper, “Vaccines for zoonoses: a one Health paradigm” http://www.onehealthinitiative.com/publications/2ST26%20B%20Kaplan%20-%208877.pdf published in SciTech Europa Quarterly Issue 26 – March 2018.

For example, on March 7, 2018, we heard from Dr. Tony Fauci, director of the National Institute of Allergy and Infectious Diseases, who writes,

“Thank you for sharing the article about [Dr.] Tom Monath’s work.  It is really well done, and captures the important contributions of our long-time friend and collaborator. 

…we have long embraced a one-health paradigm at NIAID, especially in the realm of emerging and re-emerging diseases, most of which are zoonoses and must be studied in the context of the ecosystems humans share with microbes, non-human hosts, vectors, reservoirs and other actors.  Many of the research efforts about which I speak and write almost daily fall under the one health rubric, in that our studies are multi-disciplinary and have benefits not only for humans but for other species, agriculture, and other aspects of society and the environment.   

The Hendra virus vaccine for horses is a key example of a one health approach to the control of human disease. We supported development and evaluation of a vaccine for horses with the potential for breaking the chain of HeV transmission from bats to horses to humans, thereby protecting horse, human, and environmental health.

Certainly much of what we do in influenza is “one health” in its focus --  such as the work of  Centers of Excellence for Influenza Research and Surveillance (CEIRS).  And influenza vaccine research informs not only human vaccines for seasonal and pandemic flu, but also vaccines for animals.

Another important area is our Ebola work, which is focused at preventing virus transmission into the human and great ape populations, notably via vaccine development focused at protection of humans and endangered wildlife, but also by studies to understand ebolavirus spillover dynamics; by gorilla carcass surveillance (to establish the cause of great-ape mortality); and via outreach to  local populations (to educate the local populations and thereby prevention of Ebola transmission into the human populations).

Our work on MERS-CoV [Middle East respiratory syndrome coronavirus] is focused on understanding the transmission of MERS-CoV into the human population and effective countermeasure design, including the development of vaccines and vaccination strategies for humans and dromedary camels.   Solving the MERS-CoV spike structure has  provided a potential vaccine antigen that could be applied to humans and animals (camels).  Interestingly, this antigen also appears to work for other veterinary CoV like Porcine epidemic diarrhea virus (PEDV).  

Studies of West Nile virus has resulted in candidate human vaccines, but also licensed equine vaccines that have been of great utility….”

_________

Note: On March 8, 2018, Dr. Fauci testified at a hearing of the U.S. Congress House Energy and Commerce Committee titled, “Examining U.S. Public Health Preparedness for and Response Efforts to Seasonal Influenza” http://bit.ly/2G6sAuo in Washington, DC (USA).


An Outstanding International One Health leadership team … The One Health Platform Foundation (OHP) - Thursday, March 08, 2018

An Outstanding International One Health leadership team …

 

The One Health Platform Foundation (OHP):

https://onehealthplatform.com/ohp/who-we-are/management-board

“The initiators of the One Health Platform are Prof. Ab Osterhaus (chair), Prof. John MacKenzie (vice-chair) and Mrs. Chris Vanlangendonck (daily management and communication). Together, they form the organization’s management board.

Dr. Ab Osterhaus is one of the world’s leading virologists. His interest in the One Health concept culminated in his current position as the CEO of Artemis One Health Foundation and professor of wildlife virology and virus discovery at the Utrecht University. He is also the director of the newly established Center for Infection Medicine and Zoonoses Research at the University of Veterinary Medicine in Hannover, Germany. To foster cooperation in all aspects of one health, Ab Osterhaus has joined forces with professor, Dr. John Mackenzie (Curtin University, Australia), who has an outstanding international reputation in the field of microbiology and its impacts on public health. Complementing the scientific knowledge of Ab Osterhaus and John MacKenzie is Chris Vanlangendonck’s expertise in the field of science communication, management strategies and organizational dynamics. She is the director of Semiotics, the Belgium-based agency that provides strategic communication advice to scientists, scientific organizations and academic institutions. …”

OHP is currently leading the development and program planning for the 5th International One Health Congress https://onehealthplatform.com/international-one-health-congress in Saskatoon, Canada June 22-25, 2018 in coordination and together with the extraordinary Canadian representative planners and VIPs from the University of Saskatchewan, Southern African Centre for Infectious Diseases and Surveillance (SACIDS), University of Calgary and Saskatoon, SK’s On Purpose Events http://onpurpose.ca/about-us/.

Note that members of the OHP’s Scientific Advisory Board https://onehealthplatform.com/ohp/who-we-are/scientific-advisory-board include:  Dr. Tom Monath [MD] http://www.onehealthinitiative.com/publications/2ST26%20B%20Kaplan%20-%208877.pdf who is a co-founding member of the One Health Initiative Autonomous pro bono team; Dr. David L. Heymann [MD], Editor, Control of Communicable Diseases Manual and Director, U.K. Health Protection Agency (United Kingdom), Dr. Martyn H. Jeggo [BVetMed, PhD], Director, Geelong Centre for Emerging Infectious Diseases, Deakin University Medical School, Melbourne, Australia, and Dr. Lawrence C. Madoff [MD], Editor, ProMED-mail, Professor of Medicine at the University of Massachusetts Medical School and an infectious disease public health physician (USA)... are distinguished members of the OHI teams Advisory Board http://www.onehealthinitiative.com/advBoard.php.

In addition, the OHP is host to the “One Health Official Journal of the One Health Foundation” http://www.journals.elsevier.com/one-health.

OHP works collaboratively with the U.S. One Health Commission (OHC) and the One Health Initiative Autonomous pro bono Team (OHI) to foster the worldwide yearly “One Health Day”

http://www.onehealthinitiative.com/gfx/OneHealthDay.jpg

 

 

 

 

 


Federal Panel Passes Antibiotic-Resistant Bacteria Resolutions RE: One Health - Saturday, March 03, 2018
 
Federal Panel Passes Antibiotic-Resistant Bacteria Resolutions
"Although initiated through executive order, we unanimously recommend that the PACCARB be codified into law to sustain the One Health partnerships formed and continue its mission to produce reports and recommendations that influence federal CARB-related activities, both domestic and abroad," ...
Google Plus Facebook Twitter

 


“Vaccines for zoonoses: a one Health paradigm” - Thomas P. Monath, MD, One Health Initiative Team - Friday, March 02, 2018

Scitech Europa

SciTech Europa Quarterly Issue 26 – March 2018

“Vaccines for zoonoses: a one Health paradigm” – Pages 227-229

See http://www.onehealthinitiative.com/publications/2ST26%20B%20Kaplan%20-%208877.pdf

... describes some of the achievements of the One Health Initiative team’s Dr. Thomas P. Monath, who is also launching a new and exciting vaccine company.

“One of the One Health Initiative team’s co-founders and leaders is an internationally-recognised eminent physician virologist and vaccinologist, Thomas P. Monath, MD.  From 2014-2017, Monath was Chief Scientific Officer and Chief Operations Officer of the Infectious Disease Division at NewLink Genetics Corporation, a cancer immunotherapy company. He currently serves as a Consultant to BioProtection Systems/NewLink Genetics Corp. In September 2014 VaccineNation.org identified Monath as second among the 50 most influential people in the vaccines industry.1,2  …”

Article originally published on: www.scitecheuropa.eu/vaccines-zoonoses-one-health-initiative/84008/
Reproduced by kind permission of Pan European Networks Ltd, www.scitecheuropa.eu/

© Pan European Networks 2018


One health: Joint health research - Wednesday, February 28, 2018

EurekAlert! Science News

A service of the American Association for the Advancement of Science

 

https://www.eurekalert.org/pub_releases/2018-02/bfif-ohj022818.php

Public Release: 28-Feb-2018

One health: Joint health research

BfR, FLI and RKI support the European program for the reduction of infectious diseases in humans and animals

BfR Federal Institute for Risk Assessment

Share

 Print  E-Mail

"Antimicrobial resistance and threats through new pathogens are controversial examples of the extent to which the health and illness of humans, animals and the environment are linked together," says Professor Dr. Dr. Andreas Hensel, President of the German Federal Institute for Risk Assessment (BfR). "A joint European research programme under the auspices of One Health can help to counter microbial risks effectively." The German partners of the European Joint Programme on One Health are the BfR, the Friedrich Loeffler Institute and the Robert Koch Institute.

https://www.anses.fr/en/content/anses-will-coordinate-european-joint-programme-one-health-european-research-programme-0

The goal of the European Joint Programme (EJP) is to build up a European platform for One Health which satisfies the needs of European and national political decision makers and interest groups (stakeholders). To this end, European institutions from the fields of medicine, veterinary medicine and consumer health protection in the food sector are to expand their cooperation in order to achieve progress in the containment of foodborne zoonoses (infections transferred between humans and animals), antimicrobial resistance and new infection hazards (emerging threats).

The One Health concept takes into account the close link between human health, animal health and the environment. Accordingly, the close connection between the safety of feeds and foods and human and animal health and environmental contamination is observed. The examination of infectious pathogens which can be transferred from animals to humans is an important focal point of this EJP, a new research programme within the EU framework programme for research and innovation "Horizon 2020" sponsored by the European Commission. The One Health EJP (Grant Agreement 773830) is headed by the French Agency for Food, Environmental and Occupational Health and Safety (ANSES).

The cooperation between the 40 partners is to be strengthened by the programme. Each partner also has reference tasks, which means that they set the yardstick for examinations. They already form an organised network and represent a research community in the thematic areas of foodborne zoonoses, antimicrobial resistance and emerging threats. Over a total period of five years, a sum of € 90 million is to be spent on activities within this network. 50% of the costs are being provided by the European Commission with the other half being carried by each respective member state.

The One Health EJP will generate scientific data, methods and software programs which can be used by national and European institutions to assess health risks and possible preventive measures. An exchange with other large-scale projects sponsored by the European Commission will be guaranteed at the same time. One of the tasks will be the efficient and regular transfer of knowledge between the research community and national authorities, as well as international and European stakeholders.

BfR sub-projects

A further goal of the One Health EJP is the expansion of collaboration between the institutes through interdisciplinary cooperation. This is to be realised through joint research projects and integrative schemes, as well as basic and further training measures. The BfR is involved in five research projects and two integrative schemes and is heading the "Science to Policy Translation" work package, in which measures for the best possible transfer of results from the research projects and integrative schemes to the stakeholders involved in the areas of foodborne zoonoses, antimicrobial resistance and emerging threats are to be developed.

The BfR is also coordinating the integrative project "ORION" (One health surRveillance Initiative on harmOnisation of data collection and interpretation). The main focus of this project is the exchange of data and information generated during the monitoring, collection and interpretation of data on health and wellbeing. Cooperation among the institutions is also being further improved through the cooperation of 13 institutes from seven countries active in the fields of public health and veterinary medicine.

###

About the BfR

The German Federal Institute for Risk Assessment (BfR) is a scientifically independent institution within the portfolio of the Federal Ministry of Food and Agriculture (BMEL) in Germany. It advises the Federal Government and Federal Laender on questions of food, chemical and product safety. The BfR conducts its own research on topics that are closely linked to its assessment tasks.

This text version is a translation of the original German text which is the only legally binding version.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

 


Antimicrobial resistance in zoonotic bacteria still high in humans, animals and food, say ECDC and EFSA - Needs "EU One Health Action Plan against antimicrobial resistance" - Tuesday, February 27, 2018

Home

February 27, 2017

Read full article at https://www.efsa.europa.eu/en/press/news/180227         

Antimicrobial resistance in zoonotic bacteria still high in humans, animals and food, say ECDC and EFSA

https://www.efsa.europa.eu/sites/default/files/styles/news_individual_node_image/public/news/shutterstock_483410542%20MRSA.jpg?itok=apEySPqj

Bacteria from humans and animals continue to show resistance to antimicrobials according to a new report published today by the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC). The report highlights some emerging issues and confirms antimicrobial resistance as one of the biggest threats to public health, mainly by reducing the effectiveness of treatment options.

Vytenis Andriukaitis, European Commissioner for Health and Food Safety reaffirmed his commitment to tackle AMR: “Levels of antimicrobial resistance still differ significantly from one EU country to another. To win the fight, we need to join our efforts and implement stringent policies on the use of antibiotics across sectors. It is vital that we all renew our commitment to fight antimicrobial resistance by focusing on the key areas set out in the EU One Health Action Plan against antimicrobial resistance.

Among the new findings, based on data from 2016, are detection of resistance to carbapenems in poultry, an antibiotic which is not authorised for use in animals, and of ESBL-producing Salmonella Kentucky with high resistance to ciprofloxacin in humans, which was reported for the first time in four countries. ...


STUDENT TEAMS FROM MAKERERE AND IOWA STATE WIN THE 2017 ONE HEALTH DAY STUDENT EVENT COMPETITION - One Health Commission - One Health Initiative Team - One Health Platform Foundation Monday, February 26, 2018 - Monday, February 26, 2018

http://www.onehealthinitiative.com/gfx/pdfGraphic.jpg

STUDENT TEAMS FROM MAKERERE AND IOWA STATE WIN THE 2017 ONE HEALTH DAY STUDENT EVENT COMPETITION

One Health Commission - One Health Initiative Team - One Health Platform Foundation

Monday, February 26, 2018.

 

 

 

 

                                                                                                                                                                                

 

26 February 2018     

 

Contact(s):

Cheryl Stroud, +1 984-500-8593 (USA), cstroud@onehealthcommission.org

Chris Vanlangendonck, +32 475 81 38 59 (Belgium), c.vanlangendonck@onehealthplatform.com

 

STUDENT TEAMS FROM MAKERERE  AND IOWA STATE WIN THE 2017 ONE HEALTH DAY STUDENT EVENT COMPETITION

The second annual global One Health Day, held on 3 November 2017, generated over 110 events in over 28 countries. Officially launched in April 2016 by three leading international One Health groups, the One Health Commission, the One Health Initiative Autonomous pro bono Team, and the One Health Platform Foundation, this initiative has grown into an annual, global platform for One Health advocates to educate about One Health and One Health challenges. While One Health events happening any time of the year can be registered to celebrate One Health Day, competing student led events must happen within a September 1 to November 30 window.

Today, the One Health Day Coordinating Team enthusiastically announces the winners of the 2017 One Health Day Student Events Competition. Competing groups had to meet a set of qualifying criteria and were required to submit a post-event summary. The One Health Day organizers were impressed with the work of the Student Event teams, and, based on an objective assessment, two teams are each being awarded a $2,000 prize. The winning 2017 One Health Day Student Event Competition teams are: the Makerere University One Health Student Innovation Club, which organized a Rabies Vaccination and Awareness Campaign in Uganda, and Iowa One Health for organizing the second Iowa One Health Conference.

Prizes will be officially awarded during a live event at the 5th International One Health Congress, which will be held in Saskatoon, Canada, from 22 to 25 June 2018. The 2018 One Health Day Student competition will be launched in early April and will have a slightly different set of requirements.

A special word of thanks goes out to the One Health Day Student Event Judges for lending their names and expertise to this important endeavor:

  • Prof. David Heymann, Chatham House, UK
  • Prof. Linfa Wang, Duke-NUS Medical School, Singapore
  • Prof. Tammi Krecek, Texas University
  • Prof. Daniel Lucey, Georgetown University Medical Center (GUMC)
  • Prof. Peter Rabinowitz, Center for One Health Research, University of Washington

More information about One Health Day is available online at www.onehealthday.org

###

About One Health Day

One Health Day answers the urgent need for a One Health trans-disciplinary approach towards solving today’s critical global health challenges. It is a timely initiative that gives scientists and advocates a powerful voice for moving beyond current provincial approaches to emerging zoonotic infectious diseases, antimicrobial resistance, climate change, environmental pollution, food safety, comparative/ translational medicine and many other problems, to a holistic default way of doing business.

About One Health

One Health is a movement to forge co-equal, all-inclusive collaborations, in both research and applied sciences, between human and animal health arenas, chemical, engineering and social scientists, dentists, nurses, agriculturalists and food producers, wildlife and environmental health specialists and many other related disciplines, assembled under the One Health umbrella. As early as 2010 the World Bank recognized and published documentary evidence supporting benefits of a One Health approach in disease prevention, public health and global security. Today, the One Health approach is being increasingly accepted by numerous major international organizations such as the World Medical Association (WMA), the World Veterinary Association (WVA), the World Health Organization (WHO), the Food and Agricultural Organization of the United Nations (FAO), the World Organization for Animal Health (OIE), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and U.S. Department of Agriculture (USDA). Many other supporting organizations can be found at http://www.onehealthinitiative.com/supporters.php.


Top epidemic-prone diseases without sufficient counter measures - World Health Organization (WHO), February 12, 2018 - Thursday, February 22, 2018

http://www.onehealthinitiative.com/gfx/htmlGraphic.jpg

Top epidemic-prone diseases without sufficient counter measures

World Health Organization (WHO) - Feb 12 2018

 

“The value of a One Health approach was stressed, including a parallel prioritization processes for animal health. Such an effort would support research and development to prevent and control animal diseases minimising spill-over and enhancing food security. The possible utility of animal vaccines for preventing public health emergencies was also noted.”

 

http://www.who.int/blueprint/priority-diseases/en/#.WoHmhcOoiSg.twitter

Top epidemic-prone diseases without sufficient counter measures

12 February 2018 – World Health Organization (WHO) releases its 2018 list of priority pathogens that have the potential to cause a public health emergency and which have no, or insufficient, countermeasures. WHO calls on the medical community to unite in greater R&D efforts for these 8 diseases to develop treatments and vaccines to help control outbreaks.


 
One Health Initiative
Home | About One Health | Mission Statement | One Health News | AVMA Task Force Report | One Health Newsletter |
Publications | Supporters | Supporter Endorsements | Upcoming Events | Contact Us